Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the “2022 Best Places to Work.”

“This recognition validates our efforts to build a great corporate culture, since employees are the ones surveyed for this honor,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, Inc. “We see this as an opportunity to highlight the great work we’re doing to improve health and bring innovative treatments to patients. Our people are the most important part of fulfilling that mission.”

The Philadelphia Business Journal partnered with Quantum Workplace to identify Greater Philadelphia’s Best Places to Work. This year’s list includes 76 companies from across the region, ranked by employee feedback. Nominated by the public, employees from each company were surveyed and the results were evaluated before creating the list.

Quantum Workplace’s survey measures each company’s culture and takes into consideration compensation, benefits and trust in senior leadership across five different categories based on business size. Ocugen is grouped in the Greater Philadelphia area’s medium-sized businesses (50-99 employees). Winners of each category will be named on July 28 at an awards ceremony in Philadelphia.

Career opportunities at Ocugen can be found on the Company’s website: https://ocugen.com/about/.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent / Daniel Kontoh-Boateng (Investor)
jnugent@tiberend.com
dboateng@tiberend.com

Dave Schemelia (Media)
dschemelia@tiberend.com